CooperVision Surgical
This article was originally published in The Gray Sheet
Executive Summary
Argus Biomedical's AlphaCor artificial cornea will be the premier offering of Cooper's new ophthalmic surgical division. Cleared via 510(k) in 2002, AlphaCor is suitable for approximately 20,000 corneal implant patients each year, Cooper estimates. Through the purchase of Argus assets, announced Feb. 24, Cooper also acquired AlphaSphere soft orbital implants, still under development. Meanwhile, Ciba Vision divested most of its surgical business in early February, with French firm Ioltech, SA picking up the Vivarte refractive lens family along with several other lenses and surgical product lines...
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.